Mini-invasive Preventive Fixation of the Contralateral Femoral Neck in Patients Operated on for a Femoral Neck Fracture (PREFIX)

In France, the annual incidence of hip fracture is about 80 000 with more than 75% of these fractures occurring in patients aged 80 years old or more. About 10% percent of patients presenting with a hip fracture will sustain a contralateral hip fracture, most within 3 years. The consequences of a hip fracture are dramatic: 20% of patients die in the first year and less than half those who survive regain their previous level of function. Hip fractures are invariably associated with chronic pain, reduced mobility, disability, and an increasing degree of dependence. The efficacy of pharmacological treatments to prevent a contralateral hip fracture is marginal and postponed and compliance is known to be poor.

Osteoporosis is associated with cortical thinning and trabecular bone loss. Therefore, the mini-invasive preventive fixation (MIPF) of the contralateral femoral neck is appealing. The effect is immediate and compliance is certain. Morbidity is minimal because it is performed during the same operation as the fixation of the femoral neck fracture.

The main objective of this study is to determine whether the mini-invasive preventive fixation (MIPF) of the contralateral femoral neck in patients having a femoral neck fracture is superior to no fixation regarding the occurrence of a contralateral hip fracture within 3 years.

Study Overview

Study Type

Interventional

Enrollment (Anticipated)

812

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact Backup

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

80 years and older (Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • women and men
  • 80 years or older
  • operated on for a femoral neck fracture
  • presenting one, or more, added clinical risk factor of hip fracture*
  • a fragility fracture in the past five years
  • a history of fall in the past 12 months (not considering the fall that led to the present fracture)
  • a very high risk of falling: use of psychoactive medication or impaired vision or impaired neuromuscular function
  • BMI lower than 20kg/m2
  • giving her/his consent.
  • affiliated to the social security

Exclusion Criteria:

  • history of a contralateral proximal femoral fracture
  • history of a surgical operation of the contralateral proximal femur
  • ongoing infection (bone or soft-tissue) on the contralateral hip
  • contraindication of MIPF of the contralateral hip
  • non ambulatory patients
  • patients already included in the study
  • patients with contraindication to the medical devices under evaluation
  • patients not suitable for a surgical procedure (including not suitable for an anaesthetic)
  • patients with a benign or malignant bone lesion of the contralateral femur
  • patients included in another clinical research which could directly have an effect on the femoral neck bone strength
  • patients presenting with a grade 4 Kellgren-Lawrence osteoarthritis of the contralateral hip and reporting significant clinical symptoms
  • patients with an life expectancy of less than 3 months
  • patients with a legal representative (tutorship or guardianship) and insane patients will be excluded

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Prevention
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
No Intervention: No fixation
Experimental: Preventive fixation of the contralateral femoral neck
Mini-invasive preventive fixation of the contralateral femoral neck : 6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients
6.5mm titanium cannulated self-tapping/self-drilling screws (Stryker Trauma and Depuy Synthes) : 2 screws per patients

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Cumulative incidence of a contralateral fracture of the proximal femur
Time Frame: at 3 years after randomization
at 3 years after randomization

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Mortality
Time Frame: within 3 years after randomization
within 3 years after randomization
Proportion of patients requiring surgery on the contralateral proximal femur regardless the reason
Time Frame: within 3 years after randomization
within 3 years after randomization
Patient's autonomy
Time Frame: at 3 months after randomization
Patient's autonomy will be assessed using the AGGIR scale. The AGGIR scale has 10 physical and mental variables and seven variables relating to domestic and social activities; the former are discriminative and the latter illustrative variables. The rating depends on the person doing the activity on her/his own; however, material and technical aids are allowed (glasses, wheelchair, etc). Each variable can take one of three modalities: A (perform alone), C (cannot perform alone), and B (can perform alone but on conditions).
at 3 months after randomization
Patient's autonomy
Time Frame: at 1 year after randomization
Patient's autonomy will be assessed using the AGGIR scale. The AGGIR scale has 10 physical and mental variables and seven variables relating to domestic and social activities; the former are discriminative and the latter illustrative variables. The rating depends on the person doing the activity on her/his own; however, material and technical aids are allowed (glasses, wheelchair, etc). Each variable can take one of three modalities: A (perform alone), C (cannot perform alone), and B (can perform alone but on conditions).
at 1 year after randomization
Patient's autonomy
Time Frame: at 2 years after randomization
Patient's autonomy will be assessed using the AGGIR scale. The AGGIR scale has 10 physical and mental variables and seven variables relating to domestic and social activities; the former are discriminative and the latter illustrative variables. The rating depends on the person doing the activity on her/his own; however, material and technical aids are allowed (glasses, wheelchair, etc). Each variable can take one of three modalities: A (perform alone), C (cannot perform alone), and B (can perform alone but on conditions).
at 2 years after randomization
Patient's autonomy
Time Frame: at 3 years after randomization
Patient's autonomy will be assessed using the AGGIR scale. The AGGIR scale has 10 physical and mental variables and seven variables relating to domestic and social activities; the former are discriminative and the latter illustrative variables. The rating depends on the person doing the activity on her/his own; however, material and technical aids are allowed (glasses, wheelchair, etc). Each variable can take one of three modalities: A (perform alone), C (cannot perform alone), and B (can perform alone but on conditions).
at 3 years after randomization
Patient's function
Time Frame: at 3 months after randomization
Patient's function will be assessed using the Parker score. The Parker scale assessment of mobility rates three questions: able to get about the house; able to get out of the house; able to go shopping. Each question may be answered as "no difficulty", with an aid"; "with the help from another person"; "not at all". Answer are weighted from 3 (no difficulty) to 0 (not at all). The maximum mobility score is 9; the lowest is 0.
at 3 months after randomization
Patient's function
Time Frame: at 1 year after randomization
Patient's function will be assessed using the Parker score. The Parker scale assessment of mobility rates three questions: able to get about the house; able to get out of the house; able to go shopping. Each question may be answered as "no difficulty", with an aid"; "with the help from another person"; "not at all". Answer are weighted from 3 (no difficulty) to 0 (not at all). The maximum mobility score is 9; the lowest is 0.
at 1 year after randomization
Patient's function
Time Frame: at 2 years after randomization
Patient's function will be assessed using the Parker score. The Parker scale assessment of mobility rates three questions: able to get about the house; able to get out of the house; able to go shopping. Each question may be answered as "no difficulty", with an aid"; "with the help from another person"; "not at all". Answer are weighted from 3 (no difficulty) to 0 (not at all). The maximum mobility score is 9; the lowest is 0.
at 2 years after randomization
Patient's function
Time Frame: at 3 years after randomization
Patient's function will be assessed using the Parker score. The Parker scale assessment of mobility rates three questions: able to get about the house; able to get out of the house; able to go shopping. Each question may be answered as "no difficulty", with an aid"; "with the help from another person"; "not at all". Answer are weighted from 3 (no difficulty) to 0 (not at all). The maximum mobility score is 9; the lowest is 0.
at 3 years after randomization
Proportion of patients receiving an antiosteoporotic treatment
Time Frame: at 3 months after randomization
at 3 months after randomization
Number of falls since the last follow-up visit
Time Frame: at 3 months after randomization
at 3 months after randomization
Number of falls since the last follow-up visit
Time Frame: at 1 year after randomization
at 1 year after randomization
Number of falls since the last follow-up visit
Time Frame: at 2 years after randomization
at 2 years after randomization
Number of falls since the last follow-up visit
Time Frame: at 3 years after randomization
at 3 years after randomization
Pain on the contralateral hip
Time Frame: at 3 months after randomization
Patients will be asked to rate the level of pain of the contralateral hip using a visual analogic scale, which goes from 0 (no pain) to 10 (maximum pain imaginable).
at 3 months after randomization
Pain on the contralateral hip
Time Frame: at 1 year after randomization
Patients will be asked to rate the level of pain of the contralateral hip using a visual analogic scale,, which goes from 0 (no pain) to 10 (maximum pain imaginable).
at 1 year after randomization
Pain on the contralateral hip
Time Frame: at 2 years after randomization
Patients will be asked to rate the level of pain of the contralateral hip using a visual analogic scale,, which goes from 0 (no pain) to 10 (maximum pain imaginable).
at 2 years after randomization
Pain on the contralateral hip
Time Frame: at 3 years after randomization
Patients will be asked to rate the level of pain of the contralateral hip using a visual analogic scale,, which goes from 0 (no pain) to 10 (maximum pain imaginable).
at 3 years after randomization

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Anticipated)

September 1, 2020

Primary Completion (Anticipated)

September 1, 2023

Study Completion (Anticipated)

September 1, 2025

Study Registration Dates

First Submitted

May 26, 2020

First Submitted That Met QC Criteria

May 28, 2020

First Posted (Actual)

May 29, 2020

Study Record Updates

Last Update Posted (Actual)

May 29, 2020

Last Update Submitted That Met QC Criteria

May 28, 2020

Last Verified

May 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

UNDECIDED

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Femoral Neck Fractures

3
Subscribe